tradingkey.logo


111 Inc

YI

6.800USD

-0.120-1.73%
āļ›āļīāļ” 08/04, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
344.59MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM

āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ 111 Inc āļšāļĢāļīāļĐāļąāļ—
111 Inc is an investment holding company primarily engaged in the operation of integrated online and offline healthcare platform. The Company mainly operates its business through two segments. The Business to Customer (B2C) segment is engaged in the sale of pharmaceutical and other health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers and certain enterprise customers. The Business to Business (B2B) segment is engaged in the sale of pharmaceutical products to pharmacies on 1 Pharmacy. The Company also provides customers with online consultation and electronic prescription services through the Internet hospital 1 Clinic. The Company’s products include drugs, nutritional supplements, medical supplies and devices and other products. The Company mainly conducts its business in the domestic market.
āļ‚āđ‰āļ­āļĄāļđāļĨāļšāļĢāļīāļĐāļąāļ—
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™YI
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—111 Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļSep 12, 2018
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Junling Liu
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™1238
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒDepository Receipt
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Sep 12
āļ—āļĩāđˆāļ­āļĒāļđāđˆ3-4/F, No.295 Zuchongzhi Road
āđ€āļĄāļ·āļ­āļ‡SHANGHAI
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ Global Market Consolidated
āļ›āļĢāļ°āđ€āļ—āļĻChina
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ201203
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ862120536666
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttp://corporate.111.com.cn/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™YI
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļSep 12, 2018
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Junling Liu
āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Junling Liu
Mr. Junling Liu
Co-Chairman of the Board, Chief Executive Officer, Co-Founder
Co-Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Gang Yu, Ph.D.
Dr. Gang Yu, Ph.D.
Executive Co-Chairman of the Board, Co-Founder
Executive Co-Chairman of the Board, Co-Founder
--
--
Mr. Yang (Luke) Chen
Mr. Yang (Luke) Chen
Director
Director
--
--
Mr. Jun Luo
Mr. Jun Luo
Independent Director
Independent Director
--
--
Mr. Jian (David) Sun
Mr. Jian (David) Sun
Independent Director
Independent Director
--
--
Mr. Nee Chuan Teo, CPA
Mr. Nee Chuan Teo, CPA
Independent Director
Independent Director
--
--
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Junling Liu
Mr. Junling Liu
Co-Chairman of the Board, Chief Executive Officer, Co-Founder
Co-Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Gang Yu, Ph.D.
Dr. Gang Yu, Ph.D.
Executive Co-Chairman of the Board, Co-Founder
Executive Co-Chairman of the Board, Co-Founder
--
--
Mr. Yang (Luke) Chen
Mr. Yang (Luke) Chen
Director
Director
--
--
Mr. Jun Luo
Mr. Jun Luo
Independent Director
Independent Director
--
--
Mr. Jian (David) Sun
Mr. Jian (David) Sun
Independent Director
Independent Director
--
--
Mr. Nee Chuan Teo, CPA
Mr. Nee Chuan Teo, CPA
Independent Director
Independent Director
--
--
āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: CNYāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: CNYāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆCNY
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Product Revenues
3.51B
99.44%
Service Revenues
19.70M
0.56%
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆCNY
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Product Revenues
3.51B
99.44%
Service Revenues
19.70M
0.56%
āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 17 āļž.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 17 āļž.āļ„.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
ClearVue Partners
15.64%
First Pharmacia International
8.57%
6 Dimensions Capital Ltd.
7.15%
Zall Capital Ltd
2.82%
Tongyi Investment Holding Ltd
2.13%
Other
63.69%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
ClearVue Partners
15.64%
First Pharmacia International
8.57%
6 Dimensions Capital Ltd.
7.15%
Zall Capital Ltd
2.82%
Tongyi Investment Holding Ltd
2.13%
Other
63.69%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Corporation
15.84%
Private Equity
15.64%
Venture Capital
7.15%
Investment Advisor
0.32%
Hedge Fund
0.25%
Investment Advisor/Hedge Fund
0.22%
Research Firm
0.11%
Other
60.47%
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q2
48
2.00M
39.53%
-385.56K
2025Q1
49
2.00M
39.53%
-387.91K
2024Q4
51
2.26M
44.72%
+133.67K
2024Q3
43
1.99M
39.36%
-280.22K
2024Q2
45
2.17M
42.88%
-87.92K
2024Q1
52
2.15M
42.65%
-125.45K
2023Q4
54
2.16M
44.89%
-28.04K
2023Q3
57
2.15M
44.81%
-47.43K
2023Q2
64
2.05M
43.37%
+895.26K
2023Q1
77
2.20M
46.58%
+971.22K
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™î™Œ
āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
ClearVue Partners
792.41K
15.64%
--
--
Feb 27, 2024
First Pharmacia International
434.53K
8.57%
--
--
Mar 31, 2025
6 Dimensions Capital Ltd.
362.30K
7.15%
--
--
Feb 27, 2024
Zall Capital Ltd
143.12K
2.82%
--
--
Feb 27, 2024
Tongyi Investment Holding Ltd
107.78K
2.13%
--
--
Feb 27, 2024
Allied China Investment Ltd
94.97K
1.87%
--
--
Feb 27, 2024
J.P. Morgan Trust Company of Delaware
22.17K
0.44%
--
--
Feb 27, 2024
Renaissance Technologies LLC
12.81K
0.25%
-531.00
-3.98%
Mar 31, 2025
Connor, Clark & Lunn Investment Management Ltd.
11.34K
0.22%
+11.34K
--
Mar 31, 2025
Deuterium Capital Management, LLC
10.00K
0.2%
+10.00K
--
Mar 31, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
SPDR Portfolio Emerging Markets ETF
0%
SPDR S&P Emerging Asia Pacific ETF
0%
Invesco Golden Dragon China ETF
0%
SPDR S&P Emerging Markets Small Cap ETF
0%
SPDR Portfolio Emerging Markets ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0%
SPDR S&P Emerging Asia Pacific ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0%
Invesco Golden Dragon China ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0%
SPDR S&P Emerging Markets Small Cap ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0%
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™î™Œ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
Jan 03, 2025
Merger
10<1
Jan 03, 2025
Merger
10<1
Jan 03, 2025
Merger
10<1
Jan 03, 2025
Merger
10<1
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
Jan 03, 2025
Merger
10<1
Jan 03, 2025
Merger
10<1
Jan 03, 2025
Merger
10<1
Jan 03, 2025
Merger
10<1
KeyAI
î™